Details of the Drug

General Information of Drug (ID: DM0TZEP)

Drug Name
Bamosiran
Synonyms SYL040012
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Phase 2 [1]
Drug Type
Small interfering RNA
Sequence
>Subunit 1
CUGGAUCACAUGCACAAUGTT
>Subunit 2
CAUUGUGCAUGUGAUCCAGTT
Cross-matching ID
UNII
C8Q2RMU41O
DrugBank ID
DB12256
TTD ID
D4RD0C

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ADRB2 messenger RNA (ADRB2 mRNA) TTG8ZWP ADRB2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Glaucoma/ocular hypertension
ICD Disease Classification 9C61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 1.10E-01 0.55 0.97
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sylentis.